Item 8.01. Other Events.
On January 4, 2023, Checkpoint Therapeutics, Inc. (the "Company") issued a press
release announcing the submission of a Biologics License Application to the U.S.
Food and Drug Administration for the approval of cosibelimab, its
investigational anti-PD-L1 antibody, as a treatment for patients with metastatic
cutaneous squamous cell carcinoma ("cSCC") or locally advanced cSCC who are not
candidates for curative surgery or radiation.
A copy of the Company's press release is furnished herewith as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press Release of Checkpoint Therapeutics, Inc., dated January 4,
2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses